Beyond hazard ratios, investigators used restricted mean survival time (RMST) analysis to compare survival gains across trialed ICI combinations for mRCC.

The results of the 3-year follow-up show meaningful improvement in overall survival (OS) and progression-free survival (PFS) for tislelizumab plus chemotherapy compared with placebo plus chemotherapy.

Please provide your email address to receive an email when new articles are posted on . Nivolumab significantly prolonged PFS and OS compared with placebo for patients with relapsed malignant ...

Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX) followed by ENZ maintenance therapy in patients with newly diagnosed glioblastoma (GBM) without hypermethylation of the ...

The second-line administration of ramucirumab in combination with docetaxel has shown a statistically significant improvement in overall survival (OS) and progression-free survival (PFS), compared ...

Lorazepam use may impact progression-free survival and overall survival in patients with a range of cancers, new research suggests. Lorazepam use may impact survival outcomes in patients with a range ...

Background: An improvement in overall survival (OS) in a randomized controlled study is the gold standard endpoint for the regular approval of new treatments in MBC. Progression-free survival (PFS) ...

Please provide your email address to receive an email when new articles are posted on . Results of the phase 3 CHOICE-01 trial, presented during a ASCO Plenary Series session, specifically showed PFS ...

NEW YORK -- Rucaparib (Rubraca) turned in mixed results for survival outcomes in patients with recurrent ovarian carcinoma, according to an ARIEL3 trial update. There was a benefit for ...

Trastuzumab deruxtecan improves outcomes vs physician’s choice of treatment in patients with previously treated, HER2+, advanced breast cancer. Trastuzumab deruxtecan (T-DXd) improves outcomes when ...